Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Valproic acid-phenytoin interaction.

P N Friel, K W Leal, A J Wilensky

    Therapeutic Drug Monitoring
    |January 1, 1979
    PubMed
    Summary
    This summary is machine-generated.

    Valproic acid (VPA) reduces phenytoin (DPH) levels in epilepsy patients, potentially increasing toxicity risk. Levels may stabilize later, but monitoring is crucial for safe DPH and VPA therapy.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Singing seizures.

    Neurology·2002
    Same author

    Interictal, unifocal spikes in refractory extratemporal epilepsy predict ictal origin and postsurgical outcome.

    Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2000
    Same author

    Outcome after surgery in patients with refractory temporal lobe epilepsy and normal MRI.

    Seizure·2000
    Same author

    Valproate therapy for prevention of posttraumatic seizures: a randomized trial.

    Journal of neurosurgery·1999
    Same author

    Development of dosing guidelines for reaching selected target breath alcohol concentrations.

    Journal of studies on alcohol·1999
    Same author

    Differences in the urinary excretion of 6-beta-hydroxycortisol/cortisol between Asian and Caucasian women.

    Journal of clinical pharmacology·1999
    Same journal

    A Novel Dosing Strategy for Tacrolimus in Lung Transplant Recipients: Integrating Machine Learning with Population Pharmacokinetic Analysis.

    Therapeutic drug monitoring·2026
    Same journal

    Recommendations for Assessing Methodological Quality in Systematic Reviews of Population Pharmacokinetic Models: A Systematic Review.

    Therapeutic drug monitoring·2026
    Same journal

    Wide-Range Quantification of Belumosudil in Patients with Chronic Graft-Versus-Host Disease by High-Performance Liquid Chromatography.

    Therapeutic drug monitoring·2026
    Same journal

    Deltamethrin Placental Transfer and Seasonal Pyrethroid Exposure: A Mother-Newborn Dyad Pilot Study.

    Therapeutic drug monitoring·2026
    Same journal

    A Clustering-Based Grey Modeling Approach for Tacrolimus Concentration Prediction Under Sparse Therapeutic Drug Monitoring.

    Therapeutic drug monitoring·2026
    Same journal

    Response to Panteghini "About Analytical Performance Specifications for Immunosuppressive Drug Measurements".

    Therapeutic drug monitoring·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Clinical Pharmacy
    • Neuroscience

    Background:

    • Drug interactions are common in epilepsy management.
    • Therapeutic drug monitoring is essential for optimizing patient outcomes.
    • Valproic acid (VPA) and phenytoin (DPH) are frequently prescribed antiepileptic drugs.

    Purpose of the Study:

    • To investigate the pharmacokinetic interaction between VPA and DPH.
    • To assess the impact of VPA on DPH serum concentrations and free fraction.
    • To evaluate the clinical implications for epilepsy patients on combined therapy.

    Main Methods:

    • Gas-liquid chromatography was employed for precise quantification of DPH and VPA.
    • Therapeutic drug monitoring was conducted in an outpatient epilepsy population.

    Related Experiment Videos

  • Analysis included changes in total DPH levels and free fraction percentages.

    • Main Results:

    • VPA addition significantly decreased mean DPH levels (19.7 to 15.3 microgram/ml, p < 0.001).
    • The median free fraction of DPH was higher in patients on VPA (15.8%) compared to those on DPH alone or with phenobarbital (9.1%, p < 0.001).
    • A transient increase in DPH toxicity risk was observed upon VPA addition.

    Conclusions:

    • Concomitant administration of VPA and DPH can alter DPH pharmacokinetics.
    • Increased free DPH fraction may transiently elevate toxicity risk.
    • Close therapeutic drug monitoring is recommended for patients on combined VPA and DPH therapy.